MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$48,837K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Stock-based compensation expense
Proceeds from exercise of employ...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Deferred revenue
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-43,397
-44,503
-46,135
-27,081
Stock-based compensation expense
5,970
5,949
4,309
4,364
Depreciation
1,914
2,029
2,088
2,095
Net accretion of discounts/premiums on marketable securities
-975
-985
87
-466
Gain on disposal of property and equipment
0
0
0
0
Collaboration receivable
0
-7,000
7,000
-
Other receivables
311
9
-365
2,596
Prepaid expenses and other assets
-1,340
2,921
-1,376
-941
Accounts payable
-1,493
4,377
-10,612
8,880
Accrued expenses and other current liabilities
2,210
-3,712
8,735
4,194
Defined benefit plan liability
-36
-49
147
-235
Right-of-use assets and operating lease liabilities
-440
-434
-298
-354
Deferred revenue
-8,968
-4,209
4,218
110,216
Net cash used in operating activities
-44,114
-37,369
-43,014
100,428
Purchases of property and equipment
4,723
1,868
767
651
Purchases of marketable securities
76,074
331,997
153,659
65,969
Proceeds from maturities of marketable securities
51,937
72,868
89,360
104,758
Net cash used in investing activities
-28,860
-260,997
-65,066
38,138
Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount of 29
-
-
-
0
Proceeds from sale of common stock pursuant to the at-the-market sales agreement, net of underwriter's discount
-
-
24,250
-
Proceeds from underwritten public offering, net of underwriter's discount of 3,000
-
-
0
0
Proceeds from issuance of pre-funded warrants
-
-
0
0
Payment of common stock and pre-funded warrant issuance costs
-
-
357
0
Proceeds from exercise of employee stock options
2,600
4,522
5,361
348
Proceeds from underwritten public offering, net of underwriter's commission of 20,700
0
324,300
-
-
Payment of offering costs
0
487
-
-
Proceeds from employee stock purchase plan
611
-
370
0
Net cash provided by financing activities
3,211
328,335
29,624
348
Net decrease in cash, cash equivalents and restricted cash
-69,763
29,969
-78,456
138,914
Cash, cash equivalents and restricted cashbeginning of period
164,806
134,837
213,293
229,117
Cash, cash equivalents and restricted cash-end of period
95,043
-
-
-
Cash and cash equivalents
90,104
-
-
-
Restricted cash
4,939
-
-
-
Total cash, cash equivalents and restricted cash
95,043
164,806
134,837
213,293
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
employee stock options
$2,600K
(18471.43%↑ Y/Y)
Proceeds from employee
stock purchase plan
$611K
(67.40%↑ Y/Y)
Net cash provided by
financing activities
$3,211K
(747.23%↑ Y/Y)
Net decrease in
cash, cash...
-$69,763K
(54.92%↑ Y/Y)
Canceled cashflow
$3,211K
Stock-based compensation
expense
$5,970K
(-41.42%↓ Y/Y)
Accrued expenses and
other current...
$2,210K
(143.53%↑ Y/Y)
Depreciation
$1,914K
(-54.13%↓ Y/Y)
Prepaid expenses and
other assets
-$1,340K
(-178.23%↓ Y/Y)
Defined benefit plan
liability
-$36K
(96.24%↑ Y/Y)
Proceeds from maturities
of marketable...
$51,937K
(-39.20%↓ Y/Y)
Net cash used in
operating activities
-$44,114K
(45.00%↑ Y/Y)
Net cash used in
investing activities
-$28,860K
(61.47%↑ Y/Y)
Canceled cashflow
$11,470K
Canceled cashflow
$51,937K
Net loss
-$43,397K
(-225.46%↓ Y/Y)
Deferred revenue
-$8,968K
(91.61%↑ Y/Y)
Purchases of marketable
securities
$76,074K
(-51.56%↓ Y/Y)
Accounts payable
-$1,493K
(87.53%↑ Y/Y)
Net accretion of
discounts/premiums on marketable...
-$975K
(44.79%↑ Y/Y)
Right-of-use assets and
operating lease...
-$440K
(-3.04%↓ Y/Y)
Other receivables
$311K
(-85.84%↓ Y/Y)
Purchases of property and
equipment
$4,723K
(43.91%↑ Y/Y)
Buy us a coffee
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)